Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 7:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 1,281 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infection Prophylaxis Clear all

Conditions: HIV Infections
Interventions: IMARA HIV Prevention Intervention; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 13 Years to 17 Years · Female only
Enrollment: 188 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: HIV/AIDS
Interventions: Cabotegravir Injection; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Respiratory Infections, Gastrointestinal Diseases
Interventions: Alcohol-based hand sanitizer & quaternary ammonium wipes; Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Not listed
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections
Interventions: Lenacapavir Injection, Emtricitabine/tenofovir disoproxil fumarate (F/TDF), Emtricitabine/tenofovir alafenamide (F/TAF), Cabotegravir (CAB), Lenacapavir Tablet; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Timeline: 2026 – 2029
U.S. locations: 44
States / cities: Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 29 more

Conditions: HIV Infections
Interventions: Community Mobilization; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 12 Years to 24 Years
Enrollment: 4,472 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 4 more

Conditions: Common Cold
Interventions: 3804-250A, 3804-291; Drug
Lead sponsor: The Dial Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 411 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 2
States / cities: Paramus, New Jersey • Charlottesville, Virginia

Conditions: Opioid Use, Opioid-use Disorder, Risk Reduction, Hiv
Interventions: Suboxone, PrEP; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Charlotte, North Carolina • Durham, North Carolina • Wilmington, North Carolina

Conditions: HIV Infection, Sexually Transmitted Infection
Interventions: HIV PrEP - choice of F/TDF, F/TAF, or CAB-LA, STI PEP - Doxycycline as Doxy-PEP, 3P mHealth package, Handout about HIV PrEP options available at the site, Standard-of-care HIV PrEP counseling from qualified study staff; Drug · Behavioral
Lead sponsor: HIV Prevention Trials Network; Network
Eligibility: 18 Years to 29 Years · Male only
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Los Angeles, California • The Bronx, New York

Conditions: Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection, Coronavirus, Coronavirus Infections
Interventions: Hydroxychloroquine, Placebo; Drug · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 1,312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 2
States / cities: Minneapolis, Minnesota

Conditions: HIV Infections, Opioid Use Disorder
Interventions: Not listed
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Gustilo-Anderson Type III Open Tibia Fracture
Interventions: Irrisept (Irrigation Solution), Saline; Drug
Lead sponsor: Brett D. Crist; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Dengue
Interventions: rDEN3-3'D4delta30; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: HIV
Interventions: maraviroc; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Pre-Exposure Prophylaxis of HIV Infection
Interventions: Lenacapavir Injection, Lenacapavir Tablet, Emtricitabine/tenofovir disoproxil fumarate (F/TDF); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 9
States / cities: Los Angeles, California • San Diego, California • Miami, Florida + 6 more

Conditions: Endometritis, Cesarean Section; Infection, Wound Infection
Interventions: Azithromycin 500 mg, Mefoxin 2g; Drug
Lead sponsor: RWJ Barnabas Health at Jersey City Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Jersey City, New Jersey

Conditions: HIV Seropositivity
Interventions: Computer-based simulation training for providers, Best Practice Alert, HIV Risk Assessment, PrEP Informational Video; Behavioral
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 1,380 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Neonatal Staphylococcal Sepsis
Interventions: Pagibaximab (formerly BSYX-A110); Drug
Lead sponsor: Biosynexus Incorporated; Industry
Eligibility: 3 Days to 7 Days
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Gonorrhea, Chlamydia, Syphilis
Interventions: Doxycycline Hyclate Delayed-Release 200 mg; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 641 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 3
States / cities: San Francisco, California • Seattle, Washington

Conditions: Gingivitis, Plaque, Calculus, Dental
Interventions: RF-utilizing powered toothbrush, Control placebo with no RF; Device
Lead sponsor: Home Skinovations Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Infectious Diseases
Interventions: Observational procedures; Other
Lead sponsor: Hoskinson Health and Wellness Clinic; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Gillette, Wyoming

Conditions: Clostridium Difficile Infection
Interventions: Vancomycin, fruit juice/placebo; Drug · Dietary Supplement
Lead sponsor: Corewell Health West; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Pneumonic Plague, Preventive Therapy
Interventions: rF1V vaccine; Biological
Lead sponsor: DynPort Vaccine Company LLC, A GDIT Company; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: HIV
Interventions: Dolutegravir 0.5 mg/kg liquid suspension (starts at 0-5 days of life), Dolutegravir 5 mg Dispersible Tablets (single doses), Dolutegravir 5 mg Dispersible Tablets (chronic dose), Dolutegravir 0.5 mg/kg liquid suspension (starts at 2-5 days of life); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 8
States / cities: Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 4 more

Conditions: Wound Infection
Interventions: Cefazolin PostOperatively, Cefazolin Preoperatively; Drug
Lead sponsor: Aultman Health Foundation; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Canton, Ohio

Search by objective public record fields.

IMARA, Adapting SiHLE for Detained African American Adolescent Females

Oregon PrEP at Home Study

A Randomized Controlled Trial of a School Disinfection and Hand Hygiene Program

Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention

C2P (With Venues): Connect to Protect® Partnerships For Youth Prevention Interventions

Efficacy Trial of 3804-250A in the Prevention of Cold Illnesses

Providing Suboxone and PrEP Using Telemedicine

Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy

Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2

Infectious Disease (ID) Testing OUtreach in Carceral Hubs

Randomized Trial Comparing Irrisept to Saline Irrigation for Infection Prevention

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy Adults

Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)

Two-drug Antibiotic Prophylaxis in Scheduled Cesarean Deliveries

A Multilevel, Multiphase Optimization Strategy for PrEP (MOST:PrEP)

Safety and Pharmacokinetics Study in VLBW Neonates With BSYX-A110

Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men

ToothWave Calculus Reduction and Accumulation Prevention Study

Rapamycin and Infection-related Illness

Vancomycin Prophylaxis in Recurrent Clostridium Difficile Infection

Safety, Tolerability & Immunogenicity of the Recombinant Plague Vaccine rF1V

A Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1

Prophylactic Antibiotics for Prevention of Wound Complications Following Vulvectomy